| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.056 | 0.2 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | Ispinesib Mesylate | GDSC1000 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.038 | 0.2 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.2 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |